The INSIGHT-preAD study group

We designed a large-scale mono-centric research program using a cohort of Subjective Memory Complainers (SMC) recruited from the “INveStIGation of AlzHeimer’s PredicTors in Subjective Memory Complainers” (INSIGHT-preAD) study, a French academic university-based cohort which is part of the Alzheimer Precision Medicine Initiative (APMI) and its Cohort Program (APMI-CP) [10–13]. Participants were enrolled at the Institute of Memory and Alzheimer’s disease (Institut de la Mémoire et de la Maladie d’Alzheimer, IM2A) at the Pitié-Salpêtrière University Hospital in Paris, France. The main objective of the INSIGHT-preAD study is to explore the earliest preclinical stages of AD through intermediate to later stages until progression to conversion to first cognitive symptoms, using comprehensive clinical parameters and biomarkers associated with cognitive decline. Written informed consent was provided by all participants. The study was approved by the by the INSIGHT-preAD Scientific Committee in October 2017 as Project 48 by the INSIGHT-preAD Scientific Committee. Members of this committee at that time were, Bruno Dubois, Hovagim Bakardjian, Habib Benali, Olivier Colliot, Marie-Odile Habert, Harald Hampel, Foudil Lamari, Fanny Mochel, Marie-Claude Potier, Michel Thiebaut de Schotten). This approval process was conducted in accord with the Helsinki Declaration of 1975.

The INSIGHT-preAD study includes 318 cognitively and physically normal Caucasian individuals, recruited from the community in the wider Paris area, aged 70 to 85, with SMC. Aβ-PET investigation was performed at the baseline visit, as a mandatory inclusion criterion. Thus, all individuals enrolled into the study have SMC and are stratified as either positive or negative for cerebral Aβ deposition. At the point of the study inclusion, comprehensive baseline data were collected, namely demographic and clinical data, and APOE genotype. Exclusion criteria were: a history of neurological or psychiatric diseases, including depressive disorders. The study was conducted in accordance with the tenets of the Declaration of Helsinki of 1975 and approved by the local Institutional Review Board at the participating center. All participants or their representatives gave written informed consent for use of their clinical data for research purposes.